SuperworthBoundless Bio EPS BOLD
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$2.86
- Latest quarter, Q2 FY26
- −$1.06
- Fiscal year 2025
- −$2.61
Boundless Bio's earnings per share was −$2.86 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.06.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.61 | n/a |
| FY2024 | −$14.52 | n/a |
| FY2023 | −$40.67 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.06 | n/a | −$2.86 | |
| Q1 FY26 | −$0.60 | n/a | −$2.50 | |
| Q4 FY25 | −$0.58 | n/a | −$2.61 | |
| Q3 FY25 | −$0.62 | n/a | −$2.77 | |
| Q2 FY25 | −$0.70 | n/a | −$2.89 | |
| Q1 FY25 | −$0.71 | n/a | −$2.96 | |
| Q4 FY24 | −$0.74 | n/a | −$14.52 | |
| Q3 FY24 | −$0.74 | n/a | −$23.55 | |
| Q2 FY24 | −$0.77 | n/a | −$33.52 | |
| Q1 FY24 | −$12.27 | n/a | −$43.03 | |
| Q4 FY23 | −$9.77 | n/a | −$40.67 | |
| Q3 FY23 | −$10.71 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Boundless Bio's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BOLDBoundless Bio | −$2.86 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Boundless Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.